For these reasons, the 5th edition of the World Health Organization Classification of Haematolymphoid Tumours (WHO-HAEM5) excludes the cases with concomitant MYC and BCL6 rearrangements (without BCL2 rearrangement) from the DH entity and renames the entity as diffuse large B-cell lymphoma/high-grade B-cell lymphoma with MYC and BCL2 rearrangements (DLBCL/HGBL-MYC/BCL2) to recognise their variable morphology [8]. The gene discussed is MYC; the disease is B-cell non-Hodgkin lymphoma.